Physician profile
Mark N Durkan
NPI 1992801781
$1,661.71
in general payments reported to CMS, 2019-2025
26 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $112 · 2021: $75.41 · 2022: $268 · 2023: $324 · 2024: $216 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652 · Education: $41.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.98 |
| Education | $41.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $301.49 | 2019-2025 | |
| Celgene Corporation | $179.41 | 2022-2024 | Zeposia |
| Abbvie INC. | $157.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.44 | 2019-2024 | Entyvio |
| Pfizer INC. | $126.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.29 | 2022-2025 | Xifaxan |
| Ardelyx, INC. | $105.20 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $74.69 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $53.43 | 2025 | Dupixent |
| Ethicon US, LLC | $45.57 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $41.34 | 2023 | Rebyota |
| Qol Medical, LLC | $35.68 | 2020-2024 | Sucraid |
| Fresenius Kabi USA, LLC | $27.56 | 2023 | |
| Intercept Pharmaceuticals, INC. | $25.19 | 2019-2022 | |
| Genzyme Corporation | $24.28 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $23.93 | 2019 | |
| Celltrion USA INC. | $22.56 | 2023 | Yuflyma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $21.19 | 2022 | |
| Organon LLC | $20.28 | 2023 | Renflexis |
| Romark Laboratories, Lc | $18.88 | 2020 | |
| Alfasigma USA, INC. | $18.62 | 2020 | |
| Daiichi Sankyo INC. | $16.47 | 2022 | |
| Aimmune Therapeutics, INC. | $16.18 | 2024 | |
| Ironwood Pharmaceuticals, INC | $13.54 | 2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $13.28 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Durkan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.